Viral-vector based immunotherapies to transform the fight against cancer and infectious diseases - January, 2019 - Transgene

 
Viral-vector based immunotherapies to transform the fight against cancer and infectious diseases - January, 2019 - Transgene
Viral-vector based immunotherapies
                to transform the fight against cancer
                and infectious diseases

January, 2019
Viral-vector based immunotherapies to transform the fight against cancer and infectious diseases - January, 2019 - Transgene
Disclaimer
This presentation contains forward-looking statements, which are subject to numerous risks and uncertainties,
which could cause actual results to differ materially from those anticipated. There can be no guarantee that (i) the
results of pre-clinical work and prior clinical trials will be predictive of the results of the clinical trials currently
under way, (ii) regulatory authorities will agree with the Company’s further development plans for its therapies, or
(iii) the Company will find development and commercialization partners for its therapies in a timely manner and on
satisfactory terms and conditions, if at all. The occurrence of any of these risks could have a significant negative
outcome for the Company’s activities, perspectives, financial situation, results and development.

For a discussion of risks and uncertainties which could cause the Company's actual results, financial condition,
performance or achievements to differ from those contained in the forward-looking statements, please refer to the
Risk Factors (“Facteurs de Risques”) section of the Document de Référence, available on the AMF website
(http://www.amf-france.org) or on Transgene’s website (www.transgene.fr). Forward-looking statements speak
only as of the date on which they are made and Transgene undertakes no obligation to update these forward-
looking statements, even if new information becomes available in the future.

                                                                                                                      2
Viral-vector based immunotherapies to transform the fight against cancer and infectious diseases - January, 2019 - Transgene
Focused on enhancing our leadership in viral vector-based
immunotherapies
   Mature Clinical Assets   Early-Stage Clinical   Technology Platforms
                                  Assets

    TG4010        TG4001

                                  TG6002
   Pexa-Vec       TG1050

                                                        First candidates
                                                        in clinic in 2019   3
Viral-vector based immunotherapies to transform the fight against cancer and infectious diseases - January, 2019 - Transgene
World leader in viral-vector based immunotherapies
                      Experience driven innovation
               Clinical pipeline               Our new cutting edge
                                               technology platforms

                   TG 4010
 THERAPEUTIC
                   TG 4001
   VACCINES
                   TG 1050                                            WORLD
                                   Informed                           LEADING
                                   decisions
                                                                      SCIENCE
  ONCOLYTIC        PEXA-VEC
   VIRUSES          TG6002

                                               First candidates in
                                                  clinic in 2019
                                                                                4
Viral-vector based immunotherapies to transform the fight against cancer and infectious diseases - January, 2019 - Transgene
Broad pipeline of clinical-stage immunotherapies
 Transgene strategic trials are poised to deliver key read out in 2019
                                                        Preclinical                       Clinical Phase
      Product              Indication
                                                                                  Phase 1         Phase 2             Phase 3         Next Key Milestone
 THERAPEUTIC VACCINES
            Non-small cell lung cancer –
                                                                                                                                *
                                                                                                                                           2H 2019:
 TG4010     1st line                                  + nivolumab (ICI) + CT
                                                                                                                                        ORR (35 patients)
            Recurrent HPV-positive head                                                                                                     2H 2019:
 TG4001     and neck cancers
                                                                                                                         *
                                                      + avelumab (ICI)                                                                 First efficacy date
 TG1050     Chronic hepatitis B                        + antiviral                                               **
                                                                                                                                      Potential partnership

 ONCOLYTIC VIRUSES

            Advanced HCC – 1st line
                                                                                                                                            2H 2019:
                                                      + sorafenib
 Pexa-Vec   (PHOCUS)                                                                                                            ***   Intermediary readout
                                                                                                                                           Mid 2019:
            Advanced HCC – 1st line                   + nivolumab (ICI)
                                                                                                                                        ORR (15 patients)
 TG6002     Colorectal cancer                                                                                                **               TBC

                   * Clinical collaboration / ** Rights acquired for Greater China
                   ***Transgene has commercial rights to Pexa-Vec in Europe and additional selected countries.                                                5
Viral-vector based immunotherapies to transform the fight against cancer and infectious diseases - January, 2019 - Transgene
Therapeutic Vaccines

Pioneering virus-based
immunotherapeutics
Viral-vector based immunotherapies to transform the fight against cancer and infectious diseases - January, 2019 - Transgene
Lung cancer | Better therapeutic options still needed
for non-responders (ICIs)
                                                                                            ≈30 % of 1L patients whose tumor
                                                                                            cells express high levels
                                                                                            of PD-L1 (≥ 50 %)
                                                                                            ➔ Pembrolizumab registered
Most patients still diagnosed                                                                   since 2016
at late stages, with dismal
                                                               Non-small cell lung cancer   ≈70 % of 1L patients whose tumor
prognosis                                                                                   cells express no or low levels of PD-L1
                                                                   First-line therapy
                                                                 Min. 350 K patients *      (
Viral-vector based immunotherapies to transform the fight against cancer and infectious diseases - January, 2019 - Transgene
TG4010 | Compelling lung cancer clinical data
Improved response rate & duration of response
SUCCESSFUL PHASE 2B TRIAL (RANDOMIZED, PLACEBO-CONTROLLED, 222 PATIENTS)
TG4010 in combination with chemotherapy for 1st line NSCLC

                                                                                                                                                           TG4010         Placebo
                    TG4010 + chemotherapy
                    40.9 [23.9 – 54.1] wks                                                                                                                  + CT            + CT
                                                                                                           Non-squamous (n)                                  98              98
                                                                                                             ORR                                            40%             28%
                                                                                                             Median duration of response (wks)               41              18

                     Chemotherapy (n=27)
                     18.1 [13.7 – 36.4] wks                                                                     ✓ Improved response rate
                    Placebo + chemotherapy
                    18.1 [13.7 – 36.4] wks
                                                                                                                  & duration of response

                                                                                                                ✓ Good safety profile

               Source: Quoix, E. et al., TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a
               randomised, double-blind, placebo-controlled, phase 2b/3 trial, The Lancet Oncology, Dec. 2015, (17:212)                                                             8
Viral-vector based immunotherapies to transform the fight against cancer and infectious diseases - January, 2019 - Transgene
TG4010 | Compelling lung cancer clinical data
Well positioned for further development in NSCLC
SUCCESSFUL PHASE 2B TRIAL (RANDOMIZED, PLACEBO-CONTROLLED, 222 PATIENTS)
TG4010 in combination with chemotherapy for 1st line NSCLC

 Progression-free survival (months)                                               Overall survival (months)
     Patients with non sq. tumors (n=196)                                         Patients with non sq. tumors (n=196)
                                                                                                                                                     ✓ Significant improvements
                                                                                                                                                       in PFS and OS in patients
                                                                                                                                                       in patients with non sq.
                                                                                                                                                       tumors
                           35%
                                                                                                                           36%                       ✓ Clinical efficacy
                           19%
                                                                                                                                                       in both PD-L1 negative
       TG4010 + chemotherapy
       Placebo + chemotherapy
                                                                                      TG4010 + chemotherapy
                                                                                                                            20%
                                                                                                                                                       and PD-L1 positive
                                                                                      Placebo + chemotherapy
                                                                                                                                                       patients

                                Source: Quoix, E. et al., TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a
                                randomised, double-blind, placebo-controlled, phase 2b/3 trial, The Lancet Oncology, Dec. 2015, (17:212)                                                         9
Viral-vector based immunotherapies to transform the fight against cancer and infectious diseases - January, 2019 - Transgene
TG4010 1L | To increase ORR with triple combination regimen
in patients with non sq. NSCLC expressing low levels of PD-L1 (
TG4001 | HPV-positive Head & Neck Cancers (HNSCC)
Phase 1b/2 in combination with avelumab (Bavencio®)

MVA encoding for HPV16 E6 & E7 and IL-2

              In collaboration with
                                                       Endpoints (Phase 2 part)
                                                       • Primary endpoint: Objective response rate (ORR)
                                                       • Secondary endpoints: progression-free survival (PFS), overall
                                                         survival (OS), duration of response and safety

                                                       • First patient treated in September 2017
 Principal Investigator                                • Following positive safety evaluation,
 • Pr Christophe Le Tourneau, Institut Curie             Phase 2 part ongoing and additional sites being activated
 Protocol
 • Up to 50 patients (France)
 • Multi-center, single-arm, open label trial            Phase 1 results in 4Q 2018 (n=9 patients)
 • Metastatic or refractory/recurrent HPV-16+ head &     Next clinical readout expected in 2H 2019
   neck cancer, after failure of standard therapy

                                                                                                                     11
TG1050 | Positive Phase 1 results (safety and immunogenicity)

Adeno encoding for 3 HBV antigens                       Phase 1 results presented at AASLD 2018
                                                        (n=48 patients)
Principal investigator
• Prof Fabien Zoulim, Hospices civils, Lyon (France)     ✓ Primary endpoint met: good safety profile confirmed
• Participating countries: Canada, France, Germany       ✓ TG1050 triggers T cell-based immune responses, specific
Protocol                                                   of all 3 encoded HBV antigens
• Up to 48 patients                                      ✓ Intermediate dose (1010 vp) consistently immunogenic
• Randomized safety and dose-finding study                 (≈70% of patients)
• Patients currently being treated with SoC antiviral    ✓ New preclinical data support further investigation in
  therapy                                                  combination with antivirals and immunomodulators

  Rights for Greater China acquired
  by Tasly Pharmaceuticals (July 2018)

                                                                                                                12
TG1050 | Key findings of the positive Phase 1 trial
Safety: Clinical trial primary end-point reached. Subcutaneous SD & MD injections of TG1050 in            Number of patients
NUC-suppressed CHB patients is well tolerated over the 3 DLs. No negative impact on disease               with low anti-Ad5 pre-
control, especially in the sensitive part of patients with no pre-immunity against the adenoviral         immunity per dose
vector, reinforces the robust safety profile of TG1050.                                                   group responding to at
Immunogenicity: TG1050 induces HBV-specific cellular immunity (IFN-g cells) in NUC-suppressed             least 1, 2 or 3 antigens
                                                     0
CHB patients without or with low anti-Ad5 pre-immunity.        Induced responses are specific of single
or multiple antigens expressed by TG1050 (Core/Pol & Env). Detection of Env-specific responses is
encouraging in a highly tolerogenic context for this antigen. Responses are detected following
single and multiple injections: Intermediate dose 1010 vp is consistently immunogenic (~70% of
patients).
HBsAg evolution: HBsAg decline reaches ≈0.4 log over time in 2 patients of 1010 vp group.
                                                                                                          Heatmap of ELISpot
                                                                                                          responses. Patients
                                                                                                          with low anti-Ad5
                                                                                                          pre-immunity are
                                                                                                          listed as lines and
                                                                                                          test conditions as
                                                                                                          columns

                                                                                                          Individual evolution of ELISpot responses over time in patients with low anti-Ad5 pre-immunity
                                                                                                           Detectable responses in
                                                                                                           both SD & MD cohorts at
                                                                                                           1010 & 1011 vp doses ;
                                                                                                           Env-specific responses
                                                                                                           detected despite
                                                                                                           TG1050 encoding for
                                                                                                           only small domains of
                                                                                                           Env/HBsAg as well as the
                                                                                                           very high tolerance
                                                                                                           against HBsAg
                                                                                                           characterizing CHB
                                                                                                           carriers.
Entering the field of individualized immunotherapies
using our unique proven MVA based platform
myvacTM |Individualized immunotherapy platform
  Targets patients’ neoantigens

                           Immunotherapy       MVA-based therapeutic vaccine
                                 Safety           Therapeutic class with established track-record

                                  Efficacy         Proven anti-tumor activity
                              Individualized      One cancer, One patient, One vaccine
   The advantages of
 personalised treatment        Flexible         Versatile platform and AI integration
without the drawbacks of
 autologous approaches        Clinical         First trials will start in 2019

                                                                                                    15
myvacTM | Transgene’s vaccine expertise provides the insights
needed to leverage multiple cutting edge technologies

            Artificial
          Intelligence

             Gene
            editing

            Genome
           sequencing

                                                                16
myvacTM | Targeting unique patient specific set of mutations
 • Because of deficient repair mechanisms and rapid proliferation,
   tumor cells accumulate DNA mutations
 • Some mutations lead to the generation of non-self proteins (therefore
   immunogenic)
 • These neoantigens are more immunogenic than “classical” tumor associated
   antigens

   Transgene’s myvac vaccines against neoantigens are expected
   to induce broader and stronger T cell responses

                                                                              17
myvac™ network combines bioengineering & digital transformation
Identify patients eligible                                                Manufacture
                             Secure and exploit   Select the most                                    Realize clinical
for individualized                                                        myvac™ product in
                             genomic data         relevant neo-antigens                              proof of concept
immunotherapies                                                           controlled time and cost

                                                                                                                        100

                                                                                                     Percent survival
                                                                                                                        50
                                                                                                                                                   Vaccin
                                                                                                                                                   Placebo

                                                                                                                         0
                                                                                                                              0   50         100         150
                                                                                                                                   Time (days)

                                                                                                                        World renown US
                                                                                                                         and UK clinical
                                                                                                                            centers
                                                                                                                                                               18
| Clinical protocols being finalized with 2 international KOLs

Dr Christian Ottensmeier presenting at SITC 2018   HPV negative
                                                                       After surgery
                                                   head and neck
                                                                       and adjuvant therapy
                                                      cancers

                                                                       After surgery
                                                   Ovarian cancer      and adjuvant
                                                                       chemotherapy

                                                   Trials are expected to start in 2019
                                                   (Europe & USA)

                                                                                              19
Oncolytic Viruses – Pioneered by Transgene

A new and highly promising therapeutic class in the fight against cancer.

Transgene leading the development of multifunctional OVs for the
enhanced modulation of the TME via a single therapeutic.
Pexa-Vec | Lead oncolytic virus

                                                        Global
                                             clinical development plan
 Transgene owns development
                                          HCC 1L                  Other solid tumors
 and commercialization rights
 in Europe                      • Global Phase 3 trial        • Exploratory Phase 2 trials
                                • Combination Phase 2 trial     conducted by Transgene
 Licensor: SillaJen               conducted by Transgene      • Exploratory Phase 1 trials
 (KOSDAQ: 215600)                                               led by SillaJen (RCC 2L,
                                                                CRC 2L/3L)

                                                                                             21
Pexa-Vec | Large unmet medical need in HCC

                                          First-line therapy
                                            • Sorafenib - modest activity
                                                  – ORR: 2% ; median OS: 10.7 months
Dismal prognosis
                                             • Lenvatinib recently approved with non-inferiority results (USA, EU, Japan)
                                             • Nivolumab could become a new therapeutic option: Promising activity
Better therapeutic                             in Phase 3 (still ongoing)
options needed
                                          Second-line therapy
25,000 eligible patients                    • Regorafenib
                                                – ORR: 10%; median OS: 10.6 months
in Europe*
                                            • Nivolumab approved by FDA (2017)
                                                – ORR: 18%; median OS: 15.6 months
                                            • Pembrolizumab approved by FDA (2018)
                                                – ORR: 17%, median OS: 12.9 months
              * Source: Globocan, Company estimates
                                                                                                                            22
Pexa-Vec | Key Phase 2 clinical trial results
Clinical activity demonstrated in multiple trials

      Trials with >300 patients treated with Pexa-Vec in variety of tumor types, including
      liver, colorectal and kidney

 Proof of concept for MOA: active immunotherapy

 30-patient dose-finding Phase 2 trial in HCC
 (80% of patients first-line)
  •     OS results - high dose versus low dose
           – Median OS: 14.1 (high dose) vs. 6.7 months (low dose)
           – Hazard Ratio = 0.39
           – p = 0.020
                                                                     Nature Medicine, Volume 19, Issue 2, February 2013
                                                                                                                          23
Pexa-Vec | Triggers antitumor immunity after single IV administration
Prior to planned surgery of locally advanced, poor prognosis or metastatic cancers
                                                                                                            Single IV Pexa-Vec
  Pexa-Vec shown to                                                                                                                                                   Surgery          Post-surgery

   • Selectively target tumor tissue after single IV administration                                                  d1      d2 d3               d5               d14 ± 4d              1m     3m

   • Stimulate the adaptive and innate anti-tumor immune response
                                                                                                                                 Peripheral blood samples collected
   • Induce expression of PD-L1 and PD-1 pathways
                                                                                                           n = 8 ; 3 with metastatic melanoma and 5 with colorectal cancer metastases to the liver (CRLM)

 One complete and one partial tumor pathological response                                        PBMCs exhibited robust activation by 24 hrs post-infusion
   at the time of surgery on four evaluable CRLM patients                                              • Expression of CD69 (an early activation marker) was
                                                                                                         enhanced on effector cell populations, notably NK & T cells
                                                         Tumor-specific adaptive T cell
                                                           responses (T cell Elispot)                  • Expression of PD-L1 was increased
 Presence of Pexa-Vec
      in tumor tissue                                     Patient : Mel.    CRLM                                                                                                CD69                  PD-L1
                                                            TAA : MART1 CEA
       Normal tissue
                                                          Pre-
                                                        infusion

      CRLM tissue showing expression of                1 month
      Pexa-Vec, signs of inflammation and                post-
            fibrosis, necrotic cells                   infusion

                                              Data support ongoing development of Transgene’s Vaccinia virus-based oncolytics
                        Source: Samson, A. et al, Single intravenous preoperative administration of the oncolytic vaccinia virus Pexa-Vec to prime anti-tumor immunity, ASCO 2018, June 2018                  24
Pexa-Vec | Clinical development plan in HCC - 1st line
Pivotal Phase 3 and combination Phase 2
          ➔Position Pexa-Vec with current and future standard of care

     Advanced HCC                           Conducted by       Advanced HCC        Pexa-Vec            Conducted by
                          Pexa-Vec
         1st line                                                 1st line         + Opdivo®
                          + sorafenib                           Phase 1/2          (nivolumab)
        Phase 3

 •   Multi-center Phase 3 trial in Europe, USA, Asia       •    Multi-center Phase 1/2 trial in France, Italy, USA
 •   Randomized, two-arm trial                             •    Open-label, single-arm trial
 •   Ongoing global recruitment
 •   First patient included in China in Sept. 2018
                                                           • Safety review committee expected before
                                                             year-end 2018
     First data (efficacy vs SoC) expected in 2019         • Interim analysis (15 patients) expected
                                                             mid-2019 (primary endpoint ORR)
                                                                                                                      25
Next Generation of Oncolytic Viruses

Transgene’s novel Oncolytic Viruses are based on its
optimal Vaccinia virus backbone armed with either
chemo or immuno payloads
Oncolytic viruses | Three complementary ways to act on the tumor

                                     Oncolysis
                                     Specific replication in tumor cells, and
                                     direct lysis of infected cells

                                     Immune response
                                     Induction of immunogenic cell death,
                                     engagement of both innate and
                                     adaptive anti-tumor immunity

                                     Immuno-modulating payloads delivery
       Many routes to                Targeted delivery of anti-tumor
      reach the tumor                modalities, synergistic with other
         (i.e. IV, IT)
                                     MOAs (e.g. targeted CT, or immune
                                     modulation of TME)

                                                                                27
Vaccinia virus (VV) | The optimal oncolytic backbone

               • Excellent Oncolytic activity of the Copenhagen vaccinia strain
               • Good immunological balance (Th1 vs Th2, anti-tumor vs anti-
                 viral responses, etc.)
               • Large genome capacity (up to 25 kb), to accommodate
                 multiple transgenes
               • Tumor selective replication in numerous cancer cell types, and
                 good safety profile
               • Pure cytoplasmic replication (no risk for genome integration
                 or mutagenesis)
               • Well-established processes for GMP manufacturing

                                                                              28
VVCOPTK-RR- | Targets a large spectrum of human tumors

       Replication                                             Oncolytic activity
       20 tumor cell lines, MOI 10-3, 48 hrs post-infection    10 cell lines, MOI variable, day 5 post-infection

                                                                                  100
                                   105
        Magnitude of replication

                                   104                                             80

                                                              % surviving cells
                                   103                                             60

                                   102                                             40

                                   10                                              20

                                                                                   0
                                              MIA
                                              Hela
                                           HepG2

                                          U87MG
                                             A549

                                           SKOV3

                                            PaCa2

                                         U118MG

                                             SNU5
                                           CAL33

                                          HCT116

                                         SK-Mel1
                                           PANC1

                                          Hs746T

                                          UMUC3

                                          SW780
                                             LoVo

                                             OE21

                                             OE19

                                         OVCAR3
                                           KATO3

                                                                                                                   29
TG6002
 Our VV oncolytic backbone enhanced
 by tumor targeted chemotherapy
TG6002 | Advanced OV already in the clinic
 Viral oncolysis + local production of chemotherapy

   Multiple Advantages:
                         1.   Excellent oncolytic properties
                         2.   Highly tumor selective
                         3.   IV delivery
                         4.   Targeted chemotherapy with FCU1 gene
                                  - allowing the production of 5-FU in the tumor
       TG6002

     FCU1 gene
     • Unique and proprietary                               • No FCU1 related safety issue
     • High 5-FC to 5-FU conversion rate                    • Preclinical results confirm potency

      Greater China rights acquired by Tasly Biopharmaceuticals as part of a $48 million (July 2018)

                                                                                                       31
TG6002 | Significant anti-tumor activity in multiple human cell lines

       Example: Evaluation of systemic injection of TG6002 in the colorectal cell line (LoVo)

                                                        P < 0,05

                                                                   P < 0,005

                                                        TG6002+5-FC

                                                                                      • Mice: n=12

       Similar results with other cell lines:
       pancreas (MiaPaca2); glioblastoma (U-87MG), esophaegal (OE19), stomach (HS746T), hepatocarcinoma (Hep G2)

                                                                                                                   32
TG6002 | In Phase 1/2a GI cancer clinical study
 Viral oncolysis + local production of chemotherapy administered IV

 Gastro-intestinal adenocarcinoma with liver metastasis (colon cancer)
 (Tumors known to be 5-FU sensitive)

Protocol                                                Regimen
•   Multi-center Phase 1/2a trial                       • TG6002 IV: D1, D8, D15 + 200 mg/kg/day
•   Phase 1 part (dose escalation): up to 24 patients   • Oral 5-FC prior to TG6002
•   Phase 2a part (efficacy): 35 patients               • Additional cycles until disease progression
•   Trial will include biodistribution analysis
Principal investigator                                  • INDs granted in Belgium, Spain, France
• Prof Philippe Cassier, centre Léon Bérard
  (Lyon, France)
                                                        • First patients recruited in Q4 2018
                                                        • Expected Ph 1 Readout: H2 2019

                                                                                                        33
Our new generation oncolytic products

 The Invir.IOTM Platform:
 Immuno-armed Vaccinia Virus (VV)
Multiple options for immune modulation of the tumor
micro-environment via immuno-armed oncolytic VVs

                                                               Chemokines
                                                               Favoring tumor infiltration

                                                                Undisclosed sdAbs
                                                                Unlocking local immunosuppression

    Better release of tumor Ags,
                                   Local expansion, and
    and of related immuno-
                                   activation of APC and
    stimulatory molecules
                                   effectors cells         Degradation of immunosuppressive
     hCD                        Cytokines
                                                           metabolites and cells in the TME

                                 TNFR-Ls                     Undisclosed enzyme
                                  TCEs                       ICIs
                              Agonistic sdAbs                Anti-CTLA-4

                                                                                                    35
OV encoding for anti-CTLA-4 mAb
              Improving on validated MoA of ipilimumab
Preclinical PoC                                                                                      Building a potent multifunctional OV

• Transgene’s OVs deliver functional mAb in the TME(1)                                                Improved efficacy compared to combination of
                                                                                                       separate Ab and OV (1)
• BioInvent’s full length human recombinant anti-CTLA-4
  Abs promote depletion of intratumoral Treg cells (2)                                                Longer duration of expression

                                                                                                      Expected improved tolerability owing to lower
                                                                                                       systemic antibody exposure in peripheral non-
                                                                                                       tumor compartments

                                                                                                      Indications: multiple solid cancers

                                                                                                      In late stage preclinical development

               (1) Kleinpeter P. et al., Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a scFv against programmed cell death -1 (PD-1) allows their intratumoral
               delivery and an improved tumor-growth inhibition, OncoImmunology, Oct. 2016 (5:10)
               (2) Vargas F. et al., Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies, Cancer Cell, April 2018 (33: 1-15)                                  36
Transgene to deliver multiple value-
enhancing clinical data readouts
and preclinical milestones in 2019
Significant anticipated value-creating news flow
 Portfolio to deliver news flow in the near-term

    1H 2019                                              2H 2019
                                    TG4010 1L NSCLC                    TG4010 1L NSCLC
                                    Recruitment                        ORR on 35 patients
                                    completed
Pexa-Vec + nivo 1L HCC                                                   TG6002
                                                                         Phase 1 clinical readout
Safety review
committee                                  Pexa-Vec + nivo 1L HCC
                                                                                              TG4001 SCCHN
                                           Interim analysis (ORR) on 15 patients
                                                                                              First efficacy readout

                         Pexa-Vec Phase 3 1L HCC                                            Pexa-Vec Phase 3 1L HCC
                         Futility analysis                                                  Interim analysis

                                                                                                1st product in clinic

                                                                                               1st product in clinic
                              Clinical results         Clin. trial milestone        Next generation platforms           38
Company funded to deliver multiple value generating milestones
 Key figures                                                                          Key shareholders
                                                                                      As of December 31, 2018
                   Cash and cash equivalents
 € 26.6 million
                   as of September 30, 2018

                   Operating revenues
 € 37.5 million    as of September 30, 2018                                                                            57 %
                   (incl. the sale of the TG1050 rights in China for €35.6 million)
                                                                                                                                 Free float
                                                                                                                                 43 %
  € 25 million     Expected cash burn for 2018

                                                                                                •   Market capitalization:
 Financial visibility to end September 2019                                                         ~ $200 million as of December 31, 2018
    (excl. the potential monetization of the Tasly                                              •   62.3 million shares outstanding
      Biopharmaceuticals shares - $48 million)                                                      + 0.7 million options and restricted stocks
                                                                                                •   Listed on Euronext Paris
                                                                                                •   ISIN: FR0005175080 - Ticker: TNG
                                                                                                                                                  39
Transgene| A world leader in viral-vector based immunotherapies

•   Strong late stage clinical pipeline of therapeutic vaccines
     • multiple value adding milestones expected in 2019
•   Novel myvac – individualised immunotherapy platform results from Transgene’s
    significant clinical vaccine expertise
     • First clinical trials to start in 2019
•   Well positioned to be a best-in-class in oncolytic viruses via the further
    development of TG6002 and our Invir.io platform
     • Both are based on our proprietary large capacity VVCOPTK-RR- backbone
     • First Invir.io product to enter the clinic in 2019
•   Adequate financial resources to fund business

                                                                                   40
Contact
Jean-Philippe Del
investorrelations@transgene.fr

                              @TransgeneSA                       Transgene

                      400 Boulevard Gonthier d’Andernach - Parc d’Innovation - CS80166
                      67405 Illkirch Graffenstaden Cedex France
                      Tél.: + 33 (0)3 88 27 91 21 www.transgene.fr
You can also read
NEXT SLIDES ... Cancel